We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Revolutionary Early Lung Cancer Blood Test to Enable Faster Treatment

By LabMedica International staff writers
Posted on 31 Dec 2024

Lung cancer is one of the most prevalent cancers globally, with over 2 million new cases reported in 2018. More...

Unfortunately, the majority of lung cancer cases have already metastasized by the time they are diagnosed. CT scans, which are commonly used for diagnosis, have a false positive rate of about 90%, depending on the referral process. These false positives often lead to unnecessary and costly further tests, which are typically repeated multiple times. Many of these tests are invasive, causing considerable trauma to patients. Currently, there is no approved blood-based biomarker for the early detection of lung cancer in the NHS. To address these challenges, researchers have developed a prototype blood test for diagnosing lung cancer that could help reduce false positive rates from CT scans, potentially preventing unnecessary invasive procedures and costs.

Cizzle Biotechnology (London, UK) is working on a non-invasive, affordable blood test that leverages a naturally occurring cell nuclear protein, CIZ1, which plays a role in DNA replication. A specific variant of CIZ1, known as CIZ1B, has been strongly linked to early-stage cancer presence. Cizzle's proprietary CIZ1B biomarker assay for patients with suspicious lung nodules represents a major advancement in the fight against lung cancer. This test could replace the current expensive, time-consuming, and invasive diagnostic process. Cizzle is conducting an extensive clinical evaluation of the CIZ1B biomarker lung cancer test in a high-volume, real-world clinical setting. The goal is to obtain CLIA accreditation for the test by the end of 2024, with a full launch in North America planned for April 2025.

The results from this and other planned evaluations could further demonstrate the test’s potential to distinguish between malignant and benign lung nodules, making it more widely applicable in clinical settings. Initially, the product will be an immunoassay for use in hospitals and reference laboratories, with the possibility of a point-of-care version for primary healthcare providers in the future. This test is designed to address a critical gap in clinical practice—the early detection of lung cancer when surgical removal is still a viable option. Given that nearly 5,000 people die from lung cancer daily worldwide, early detection is crucial. Cizzle's CIZ1B biomarker blood test offers a cost-effective, non-invasive solution to detect lung cancer in its earliest stages, potentially saving lives and reducing healthcare costs.

Related Links:
Cizzle Biotechnology


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.